GENFIT S.A. American Depositary Shares (GNFT)
Company News
GENFIT has signed Put Option Agreements with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs. The company has convened a general meeting of the 2025 OCEANEs holders on March 10, 2025 to approve the amendment of the terms and conditions of the 2025 OCEANEs and the closing of a royalty financing transaction.
After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of $19, up from $8. In June, Intercept's obeticholic acid (OCA) in NASH received a second CRL, prompting the company to discontinue the NASH program entirely. The move involved restructuring but positions the company to be profitable next year based on its PBC business with Ocaliva, given the CRL, this was widely expected. The analyst also notes that the company's interim Phase 2 dose-ranging data from its Ocaliva ...Full story available on Benzinga.com
It's time to look ahead to a new quarter and final half of the year. Piper Sandler offers some stock ideas to sell and buy.